New Zealand markets open in 5 hours

Vigil Neuroscience, Inc. (VIGL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
11.95-0.30 (-2.45%)
As of 10:59AM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close12.25
Open12.34
Bid12.07 x 2200
Ask12.54 x 900
Day's range11.40 - 12.34
52-week range2.18 - 18.27
Volume21,577
Avg. volume21,695
Market cap425.194M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-6.45
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est20.33
  • Simply Wall St.

    We Think Vigil Neuroscience (NASDAQ:VIGL) Can Afford To Drive Business Growth

    We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

  • GlobeNewswire

    Vigil Neuroscience to Host ALSP KOL Event on December 6, 2022

    CAMBRIDGE, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that the Company will host an adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) Key Opinion Leader (KOL) event for the investment community in New York City on Tuesday, December 6, 2022, from 8:30 a.m. – 11:30 a.m. ET. The eve

  • GlobeNewswire

    Vigil Neuroscience Reports Third Quarter 2022 Financial Results and Provides Business Update

    –Announced interim topline data from Phase 1 trial of VGL101 in healthy volunteers– –On track to initiate Phase 2 proof-of-concept trial in ALSP patients this quarter– –Received Fast Track designation from the FDA for VGL101 in patients with ALSP– –Completed $75 million PIPE from new and existing investors, extending cash runway into the first quarter of 2025– CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company commi